Arrowhead Pharmaceuticals Inc (ARWR)

NASDAQ
33.57
-0.89(-2.58%)
Pre Market
33.00
-0.57(-1.70%)
- Real-time Data
  • Volume:
    703,021
  • Day's Range:
    33.18 - 34.78
  • 52 wk Range:
    26.81 - 84.83

ARWR Overview

Prev. Close
34.46
Day's Range
33.18-34.78
Revenue
249.94M
Open
34.42
52 wk Range
26.81-84.83
EPS
-1.47
Volume
703,021
Market Cap
3.55B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
769,011
P/E Ratio
-32.96
Beta
1.35
1-Year Change
-42.21%
Shares Outstanding
105,848,963
Next Earnings Date
Dec 13, 2022
What is your sentiment on Arrowhead Pharma?
or
Market is currently closed. Voting is open during market hours.

Arrowhead Pharmaceuticals Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Arrowhead Pharmaceuticals Inc Analysis

Arrowhead Pharmaceuticals Inc Company Profile

Arrowhead Pharmaceuticals Inc Company Profile

Employees
329

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company uses a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's pipeline includes ARO-APOC3 for hypertriglyceridemia, ARO-ANG3 for dyslipidemia, ARO-HSD for liver disease, ARO-ENaC for cystic fibrosis, ARO-HIF2 for renal cell carcinoma, ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-LUNG2 for chronic obstructive pulmonary disorder, and ARO-COV for the coronavirus that causes COVID-19 and other possible future pulmonary-borne pathogens.

Read More

Analyst Price Target

Average74.08 (+120.67% Upside)
High110
Low39
Price33.57
No. of Analysts12
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellSellStrong SellStrong SellStrong Sell
Technical IndicatorsBuyBuyStrong SellSellStrong Sell
SummaryNeutralNeutralStrong SellStrong SellStrong Sell
  • go buy and hold ;)
    1
    • RDGL 0.125 By 1/16/2021 FDA will provide a final decision to grant or deny their request for breakthrough designation.
      2
      • Dilution soon?
        0
        • i think they just got a ton of $ from their new deal...doesn't mean won't dilute
          0
      • Going to 69
        0
        • Target price 76$
          1
          • Upgrade?
            0
        • Pandemic covid19 Coronavirus has created massive never ever earning opportunities for biotechs pharmaceutical companies products investments...as its 7bn human beings effected need to be protected cured...supposing usd 100 each one spends on vaccines gloves sanitizers masks its huge mount Everest of earnings for biotechs pharma vaccines companies
          1
          • All pharma biotechs to shoot upwards rocket drive like Arrowhead today.....Trump clearly pushing forward indicating Coronavirus stimulus update: Trump suggests he could back bigger relief billhttps://www.cnbc.com/id/106704892?view=story?__source=androidappshare
            0
            • Go for 57$
              0
              • Go for 20$
                2
                • it is a buy now
                  0